SequelSEC

NIKA PHARMACEUTICALS, INC NIKA

Pharmaceutical Preparations · CIK 0001145604 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$47.17K
Fiscal year ended 2023-12-31
Free cash flow
Unavailable
Fiscal year ended 2023-12-31

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.07x4th

NIKA PHARMACEUTICALS, INC (NIKA) reported revenue of $0 and net income of -$47.17K for the fiscal year ended 2023-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from NIKA PHARMACEUTICALS, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NIKA PHARMACEUTICALS, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$47.17K
Net income-$47.17K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$47.17K
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$47.17K
Selling & marketingUnavailable

Balance

NIKA PHARMACEUTICALS, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Cash & equivalents$19.60K
Total assets$19.60K
Current assets$19.60K
Total liabilities$101.74K
Current liabilities$101.74K
Total equity incl. NCI-$82.15K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

NIKA PHARMACEUTICALS, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Operating cash flow-$64.83K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$83.56K
Net change in cash$18.73K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

NIKA PHARMACEUTICALS, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.19x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NIKA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.